Alcon/$ALC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alcon
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
Ticker
$ALC
Sector
Primary listing
NYSE
Industry
Health Care Equipment and Supplies
Headquarters
Geneva, Switzerland
Employees
25,000
Website
Alcon Metrics
BasicAdvanced
$46B
40.84
$2.25
0.70
$0.22
0.20%
Price and volume
Market cap
$46B
Beta
0.7
52-week high
$99.64
52-week low
$80.48
Average daily volume
1.6M
Dividend rate
$0.22
Financial strength
Current ratio
2.701
Quick ratio
1.455
Long term debt to equity
22.821
Total debt to equity
23.634
Dividend payout ratio (TTM)
11.61%
Interest coverage (TTM)
6.78%
Profitability
EBITDA (TTM)
2,333
Gross margin (TTM)
55.58%
Net profit margin (TTM)
11.28%
Operating margin (TTM)
13.39%
Effective tax rate (TTM)
16.10%
Revenue per employee (TTM)
$400,000
Management effectiveness
Return on assets (TTM)
2.74%
Return on equity (TTM)
5.23%
Valuation
Price to earnings (TTM)
40.844
Price to revenue (TTM)
4.581
Price to book
1.65
Price to tangible book (TTM)
10.57
Price to free cash flow (TTM)
31.291
Free cash flow yield (TTM)
3.20%
Free cash flow per share (TTM)
293.70%
Dividend yield (TTM)
0.24%
Forward dividend yield
0.20%
Growth
Revenue change (TTM)
3.80%
Earnings per share change (TTM)
6.65%
3-year revenue growth (CAGR)
5.10%
3-year earnings per share growth (CAGR)
34.24%
3-year dividend per share growth (CAGR)
12.09%
What the Analysts think about Alcon
Analyst ratings (Buy, Hold, Sell) for Alcon stock.
Bulls say / Bears say
Alcon's new dry-eye drug, Tryptyr, received FDA approval in May 2025, potentially expanding its market share in the dry eye treatment sector. (reuters.com)
Analysts have set an average 12-month price target of $106.13 for Alcon, indicating a potential upside of approximately 20.25%. (marketbeat.com)
Alcon's strategic investments in fast-growing market segments, such as the PRECISION1 family and DAILIES TOTAL1 for astigmatism, have led to significant market share gains in the contact lens category. (nasdaq.com)
Alcon is experiencing inflationary pressures in electronic components, freight, labor, resins, and plastics, which are impacting the company's margins. (nasdaq.com)
The ophthalmology industry is highly competitive, with Alcon facing intense competition in both surgical and vision care businesses, including from providers of alternative medical therapies. (nasdaq.com)
Alcon's P/E ratio of 39.08 is higher than the market average of about 24.88, suggesting the stock may be overvalued compared to the broader market. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 2 Jul 2025.
Alcon Financial Performance
Revenues and expenses
Alcon Earnings Performance
Company profitability
Alcon News
AllArticlesVideos
Alcon's Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval
Business Wire·2 weeks ago
Alcon Canada Earns Global Recognition as a Top Employer
Business Wire·4 weeks ago
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alcon stock?
Alcon (ALC) has a market cap of $46B as of July 25, 2025.
What is the P/E ratio for Alcon stock?
The price to earnings (P/E) ratio for Alcon (ALC) stock is 40.84 as of July 25, 2025.
Does Alcon stock pay dividends?
Yes, the Alcon (ALC) stock pays dividends to shareholders. As of July 25, 2025, the dividend rate is $0.21783 and the yield is 0.2%. Alcon has a payout ratio of 11.61% on a trailing twelve-month basis.
When is the next Alcon dividend payment date?
The next Alcon (ALC) dividend payment date is unconfirmed.
What is the beta indicator for Alcon?
Alcon (ALC) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.